The Artificial Saliva Spray Reduces Xerostomia in Diabetes Type II
Xerostomia Due to Hyposecretion of Salivary Gland, Diabetes Mellitus, Type 2
About this trial
This is an interventional prevention trial for Xerostomia Due to Hyposecretion of Salivary Gland focused on measuring xerostomia, diabetes type II, salivary flow, antioxidant capacity of saliva, aldiamed
Eligibility Criteria
Inclusion Criteria:
- suffering xerostomia
- degree of xerostomia at least > 2 according to a semiquantal scare ranging from 0 to 6
- diabetes Type II > one year, with stabilized oral hypoglycemic therapy from at least 6 months.
- concomitant chronic diseases pertaining to dyslipidemia, cardiovascular and/or gastrointestinal diseases, and anxiety/depression were accepted provided under adequate therapy since at least 6 months.
Exclusion Criteria:
- under treatment for xerostomia or with xerostomia score < 2
- suffering from obesity (BMI > 30 kg/m2),
- cancer of any type
- drug addiction and alcoholism
Sites / Locations
- Irwin Labs, University of Chieti
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
artificial saliva spray (AS)
maritime throat spray (TT)
The randomized part of the participants who started first with the artificial saliva spray taking it three times a day for a three days treatment, followed by a wash out phase of 3 days. After wash out phase they take for three days the marine water throat spray taking it three times a day for a three days treatment.
The randomized part of the participants who started first with the marine water throat spray taking it three times a day for a three days treatment, followed by a wash out phase of 3 days. After wash out phase they take for three days the artificial saliva spray taking it three times a day for a three days treatment.